BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Esophageal cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for esophageal cancer: 191 (134 sponsors; 26 newly posted in the last 180 days, 9 stopped in the last 180 days; 16 new-entrant sponsors). Momentum score 10.2, rank 66 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 74, Phase 2 66, Phase 3 21, Phase 4 0, N/A 28.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 7 | P3 2, NA 2, P2 3 | 1 | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 6 | P3 2, P1 3, P2 1 | 0 | 2 |
| Daiichi Sankyo | 3 | P3 2, P2 1 | 0 | 0 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | 2 | P3 2 | 1 | 0 |
| Merck Sharp & Dohme LLC MRK | 6 | P2 5, P3 1 | 0 | 0 |
| Astellas Pharma Global Development, Inc. | 5 | P3 1, P2 4 | 1 | 0 |
| Bristol-Myers Squibb BMY | 4 | NA 3, P3 1 | 1 | 1 |
| Pfizer PFE | 4 | P1 3, P3 1 | 1 | 0 |
| Jazz Pharmaceuticals JAZZ | 3 | P3 1, NA 1, P2 1 | 1 | 1 |
| Beijing Konruns Pharmaceutical Co., Ltd. | 2 | P3 1, P2 1 | 0 | 1 |
| Hansoh BioMedical R&D Company | 2 | P3 1, P2 1 | 1 | 0 |
| Ono Pharmaceutical Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Shandong Boan Biotechnology Co., Ltd | 1 | P3 1 | 0 | 0 |
| Shanghai JMT-Bio Inc. | 1 | P3 1 | 0 | 0 |
| SOFIE | 1 | P3 1 | 0 | 0 |
| Sunshine Lake Pharma Co., Ltd. SBFM | 1 | P3 1 | 0 | 0 |
| Eli Lilly and Company LLY | 5 | P1 5 | 0 | 2 |
| Chongqing Precision Biotech Co., Ltd | 3 | P1 3 | 0 | 1 |
| Seagen, a wholly owned subsidiary of Pfizer | 3 | P2 1, P1 2 | 0 | 0 |
| SystImmune Inc. | 3 | P1 3 | 0 | 1 |
| AbbVie ABBV | 2 | P1 2 | 0 | 0 |
| BeOne Medicines ONC | 2 | P2 2 | 1 | 0 |
| Exelixis EXEL | 2 | P1 2 | 0 | 1 |
| I-Mab Biopharma US Limited | 2 | P1 1, P2 1 | 0 | 1 |
New-entrant sponsors: Ono Pharmaceutical Co., Ltd..
Recently stopped trials
- NCT05462873 Novartis Pharmaceuticals - terminated: Business decision and not related to safety concerns A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
- NCT04868877 Merus B.V. - terminated: The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-r Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Soli
- NCT05048368 Sunshine Lake Pharma Co., Ltd. - withdrawn: Study was withdrawn per sponsor decision after recruitment opened with no participants enrolled. Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
- NCT04949256 Merck Sharp & Dohme LLC - terminated: Trial was rendered as cancelled work ongoing in the book of business. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Me
- NCT05572684 NextCure, Inc. - terminated: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Meta
- NCT03281369 Hoffmann-La Roche - terminated: The study was closed because the sponsor decided not to continue the development of certain treatment combinations. A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metasta
- NCT03114319 Novartis Pharmaceuticals - terminated: Business reasons and not due to any safety concerns Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
- NCT06585488 BeOne Medicines - terminated: The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competi A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Met
- NCT04458259 Pfizer - terminated: Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | AP Biosciences Inc. | NCT05473156 A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion | Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squam | recruiting | 168 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06008054 A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Co | Esophageal Cancer; Gastric Cancer; Colorectal Cancer | recruiting | 376 |
| 2026-12 est. | P2/P3 | RemeGen Co., Ltd. | NCT06221748 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therap | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | recruiting | 90 |
| 2026-12 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06942767 Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophag | Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | not yet recruiting | 100 |
| 2026-12 est. | P1/P2 | One-carbon Therapeutics AB | NCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | Solid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung | recruiting | 43 |
| 2026-12 est. | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Duc | not yet recruiting | 300 |
| 2026-12-30 est. | P3 | Beijing Konruns Pharmaceutical Co., Ltd. | NCT06194734 A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | Esophageal Squamous Cell Carcinoma | recruiting | 490 |
| 2026-12-30 est. | P3 | AskGene Pharma, Inc. | NCT06206733 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma | active not recruiting | 780 |
| 2026-12-30 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | active not recruiting | 464 |
| 2026-12-30 est. | P1/P2 | Astellas Pharma Global Development, Inc. | NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metasta | active not recruiting | 240 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P2 | Jazz Pharmaceuticals JAZZ | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endome | recruiting | 200 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-01-11 est. | P3 | FutureGen Biopharmaceutical (Beijing) Co., Ltd | NCT06177041 M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or | Locally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metasta | recruiting | 486 |
| 2027-01-30 est. | P3 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06656091 A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma | Advanced Oesophageal Squamous Cell Carcinoma | not yet recruiting | 450 |
| 2027-02 est. | P1/P2 | Lumicell, Inc. | NCT02584244 Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | Colorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Cancer | active not recruiting | 66 |
| 2027-02 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT07367516 Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | Esophageal Cancer | recruiting | 105 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-17 est. | P2 | AstraZeneca AZN | NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarci | recruiting | 226 |
| 2026-11 est. | P3 | Akeso | NCT06341335 A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric and Gastroesophageal Junction Adenocarcinoma | recruiting | 506 |
| 2026-10-31 est. | P2 | Shanghai Henlius Biotech | NCT06769113 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy | Esophageal Cancer | recruiting | 102 |
| 2026-10-19 | P3 | Merck Sharp & Dohme LLC MRK | NCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Gastroesophageal Cancer | active not recruiting | 473 |
| 2026-10-01 est. | P2 | Taiho Oncology, Inc. | NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Ade | active not recruiting | 53 |
| 2026-10-01 | P1/P2 | Merus B.V. | NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and | terminated | 194 |
| 2026-10 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06474468 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer | Advanced or Metastatic Esophageal Cancer | unknown | 148 |
| 2026-10 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06423885 A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocar | HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma | active not recruiting | 64 |
| 2026-09-28 | P3 | Cinclus Pharma Holding AB | NCT07037875 A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disea | GERD (Gastroesophageal Reflux Disease) | completed | 523 |
| 2026-09 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06767800 A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advan | Gastroesophageal Adenocarcinoma | recruiting | 204 |
| 2026-08-31 | P3 | Daewon Pharmaceutical Co., Ltd. | NCT07931521 Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux Disease | Erosive Reflux Disease; GERD (Gastroesophageal Reflux Disease) | completed | 328 |
| 2026-08-31 est. | P3 | Daiichi Sankyo | NCT04704934 Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-C | Gastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | active not recruiting | 490 |
| 2026-08-26 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06577376 A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; | not yet recruiting | 252 |
| 2026-08-14 | P2 | AstraZeneca AZN | NCT07143604 A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18. | Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 33 |
| 2026-08 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT07110571 A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer | Gastric Cancer; Gastroesophageal-junction Cancer | recruiting | 200 |
| 2026-07-22 | P3 | Hoffmann-La Roche | NCT04543617 A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Follo | Esophageal Squamous Cell Carcinoma | completed | 760 |
| 2026-07-21 | P2 | Takeda TAK | NCT02616302 A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old | Gastroesophageal Reflux Disease (GERD) | completed | 71 |
| 2026-07-15 | P3 | Jazz Pharmaceuticals JAZZ | NCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal | Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma | active not recruiting | 920 |
| 2026-06-30 est. | P3 | Onconic Therapeutics Inc. | NCT07160790 Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease | Non-erosive Gastroesophageal Reflux Disease | not yet recruiting | 321 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-05-31 | P3 | AstraZeneca AZN | NCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Ad | Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 594 |
| 2026-05-27 | P2 | Microbiome Health Sciences | NCT05556824 Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD | Gastroesophageal Reflux | completed | 255 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "esophageal cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.